RAF265

RAF265 is an orally bioavailable small molecule inhibitor developed as an anticancer agent, primarily targeting wild-type and mutant (V600E) B-Raf kinase, as well as C-Raf kinase. It also inhibits other kinases including Vascular endothelial growth factor receptor 2 (VEGFR2), Platelet-derived growth factor receptor (PDGFR), Colony stimulating factor 1 receptor (CSF1R), RET proto-oncogene tyrosine-protein kinase receptor (RET), Mast/stem cell growth factor receptor Kit (c-Kit), Proto-oncogene tyrosine-protein kinase Src (Src), and Serine/threonine-protein kinase STE20 (STE20). By inhibiting these kinases—especially B-Raf V600E—RAF265 disrupts the Ras/Raf/MEK/ERK signaling pathway that is frequently upregulated in cancers such as melanoma. In addition to its antineoplastic effects through inhibition of tumor cell proliferation and induction of apoptosis, it also impairs tumor angiogenesis by blocking Vascular endothelial growth factor receptor 2 (VEGFR2) activity. Preclinical studies have shown that RAF265 can decrease expression of anti-apoptotic proteins like Bcl-2 and inhibit osteoclastogenesis. Beyond oncology applications (notably unresectable or metastatic melanoma), recent research has indicated potential antiviral activity against coronaviruses by interfering with viral entry and protein synthesis[1][2][3][4][5][7].